(E)-3-(4-Amino-3,5-dimethylphenyl)acrylonitrile hydrochloride | CAS:661489-23-2

We serve (E)-3-(4-Amino-3,5-dimethylphenyl)acrylonitrile hydrochloride CAS:661489-23-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
(E)-3-(4-Amino-3,5-dimethylphenyl)acrylonitrile hydrochloride

Chemical Name:(E)-3-(4-Amino-3,5-dimethylphenyl)acrylonitrile hydrochloride
CAS.NO:661489-23-2
Synonyms:(E)-3-(4-Amino-3,5-dimethylphenyl)acrylonitrile hydrochloride
(E)-3-(4-amino-3,5-dimethylphenyl)prop-2-enenitrile,hydrochloride
(2E)-3-(4-Amino-3,5-dimethylphenyl)acrylonitrile hydrochloride
 
Physical and Chemical Properties:
Molecular Formula C11H13ClN2
Molecular Weight 208.687
 
Specification:
Appearance:Light green crystalline powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Rilpivirine(CAS:500287-72-9).



Contact us for information like (E)-3-(4-Amino-3,5-dimethylphenyl)acrylonitrile hydrochloride chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(2E)-3-(4-Amino-3,5-dimethylphenyl)acrylonitrile hydrochloride physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(E)-3-(4-Amino-3,5-dimethylphenyl)acrylonitrile hydrochloride Use and application,(E)-3-(4-amino-3,5-dimethylphenyl)prop-2-enenitrile,hydrochloride technical grade,usp/ep/jp grade.


Related News: Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2).3-Trifluoromethylphenol manufacturer Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2).(10-(3-(naphthalen-1-yl)phenyl)anthracen-9-yl)boronic acid supplier China is now dealing with another disease outbreak — this one mostly affecting animals but also potentially deadly among people.4-benzhydryloxypiperidine vendor China is now dealing with another disease outbreak — this one mostly affecting animals but also potentially deadly among people.The quality of the drug substance determines the quality of the preparation, so its quality standards are very strict. Countries around the world have formulated strict national pharmacopoeia standards and quality control methods for their widely used drug substances.